Amgen Reports Real-World Study Results of Prolia (denosumab) for Osteoporosis Associated with High Fracture Risk
Shots:
- The real-world study presented at WCO-IOF-ESCEO 2023 evaluating Prolia vs alendronate from 478,651 postmenopausal women aged ≥66yrs. The retrospective analysis was based on a US Medicare beneficiary database
- The results showed a 36% & 43% reduction in risk of hip fractures & nonvertebral fractures, 30% in the risk of hospitalized vertebral fractures, 39% in the risk of major osteoporotic, nonvertebral & hospitalized vertebral fractures, 50% reduced risk of non-hip, nonvertebral fractures
- The analysis also showed that a longer duration of treatment with denosumab led to a greater reduction in risk of major osteoporotic fracture at 1/2/3/5yr. were 9%/12%/18%/31% and 39% overall, respectively
Ref: PRNewswire | Image: Amgen
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
